Selected clinical highlights from the 2012 ERS congress in Vienna

European Respiratory Journal

Volumn 41, Issue 5, 2013, Pages 1219-1227

  Marvisi, Maurizio ^a   Herth, Felix J F ^d   Ley, Sebastian ^e   Poletti, Venerino ^b   Chavannes, Niels H ^f   Spruit, Martijn A ^g   Clini, Enrico ^c   Cottin, Vincent ^h,i  

^a Department of Internal Medicine and Pneuumology   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Chirurgische Klinik Dr Rinecker   (Germany)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Centre of Expertise for Chronic Organ Failure   (Netherlands)

^h LOUIS PRADEL HOSPITAL   (France)

ⁱ UNIVERSITÉ LYON 1   (France)

Author keywords

Chronic obstructive pulmonary disease; End of life; Idiopathic pulmonary fibrosis; Interventional pulmonology; Primary care; Rehabilitation; Sarcoidosis

Indexed keywords

BOSENTAN; FLUORODEOXYGLUCOSE F 18; PLACEBO;

AUSTRIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG RESPONSE; ENDOBRONCHIAL ULTRASONOGRAPHY; FIBROSING ALVEOLITIS; GENERAL PRACTICE; HUMAN; IMAGE ANALYSIS; LUNG DISEASE; LUNG EMPHYSEMA; LUNG FUNCTION; LUNG SARCOIDOSIS; LUNG STRUCTURE; MEDICAL SERVICE; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL ACTIVITY; POSITRON EMISSION TOMOGRAPHY; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; PULMONARY HYPERTENSION; PULMONARY REHABILITATION; REHABILITATION CARE; REVIEW; SYSTEMIC DISEASE; THORAX RADIOGRAPHY;

CHRONIC OBSTRUCTIVE PULMONARY DISEASE; END-OF-LIFE; IDIOPATHIC PULMONARY FIBROSIS; INTERVENTIONAL PULMONOLOGY; PRIMARY CARE; REHABILITATION; SARCOIDOSIS;

AUSTRIA; EUROPE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; PRIMARY HEALTH CARE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE; SARCOIDOSIS; TERMINAL CARE; TREATMENT OUTCOME;

EID: 84877088622     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00182612     Document Type: Review

References (76)

1. Waters JA, Wang W, Marley C, et al. Different duration of corticosteroid therapy for exacerbations of COPD. Cochrane Database Syst Rev 2011; 15: CD006897.
2. Leuppi JD, Schultz P, Bingisser R, et al. Short term therapy in acute exacerbations of COPD: "REDUCED" a non-inferiority multicenter trial. Eur Respir J 2012; 40: Suppl. 56, 787s.
3. Roberts CM, Hartl S, Pozo-Rodriguez S, et al. Differences between men and women COPD adimission: evidence from the European COPD audit. Eur Respir J 2012; 40: Suppl. 56, 788s.
4. Lopez-Campos JL, Hartl S, Pozo-Rodriguez M, et al. Evaluation of multiple admissions of COPD patients: European COPD audit. Eur Respir J 2012; 40: Suppl. 56, 788s.
5. McClintock-Tiongco A, Patel A, Chakravorty I. An audit of inpatient mortality and readmission rates in acute exacerbation of COPD. Exploring the role of comorbidity and inflammatory markers. Eur Respir J 2012; 40: Suppl. 56, 788s.
6. Patel ARC, Donaldson GC, Kowlessar BS, et al. The impact of airway infection on cardiovascular risk during COPD exacerbations. Eur Respir J 2012; 40: Suppl. 56, 788s.
7. Urban M, Valipour A, Kiss D, et al. Endothelial dysfunction and systemic inflammation during acute exacerbations of COPD. Eur Respir J 2012; 40: Suppl. 56, 12s.
8. Quint J, Herrett E, Timmis A, et al. Relationship between exacerbation frequency and survival post MI in COPD patients. Eur Respir J 2012; 40: Suppl. 56, 787s.
9. Soyseth V, Bhatnagar R, Holmedahl N, et al. Acute exacerbation in COPD is associated with three fold elevation of cardiac troponin T. Eur Respir J 2012; 40: Suppl. 56, 789s.
10. Romme E, Edward L, Williams M, et al. Low CT bone radio density is associated with adverse clinical features and increased coronary artery calcification in COPD. Eur Respir J 2012; 40: Suppl. 56, 12s.
11. Haarmann H, Klarner S, Raupach T, et al. Increased sympathetic nerve activity in COPD is associated with elevated morbidity and mortality. Eur Respir J 2012; 40: Suppl. 56, 15s.
12. Singh R, Garcha D, Patel A, et al. The impact of bacterial colonization on airway inflammation in stable COPD. Eur Respir J 2012; 40: Suppl. 56, 14s.
13. Lainscak M, Edward L, Anker S, et al. Clinical impact of anaemia in patients with chronic obstructive pulmonary disease: results from ECLIPSE study. Eur Respir J 2012; 40: Suppl. 56, 13s.
14. Stolz D, Boersma W, Milenkovic B, et al. Proadrenomedullin improves the prognostic property of the BODE index. Eur Respir J 2012; 40: Suppl. 56, 288s.
15. Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J. 2010; 36: 81-88.
16. van den Borst B, Slot IG, Hellwig VA, et al. Loss of quadriceps muscle oxidative phenotype and decreased endurance in patients with mild-to-moderate COPD. J Appl Physiol 2012 [In press DOI: 10.1152/japplphysiol.00508.2012].
17. Waschki B, Spruit MA, Watz H, et al. Physical activity monitoring in COPD: compliance and associations with clinical characteristics in a multicenter study. Respir Med 2012; 106: 522-530.
18. Polkey MI, Coissi G, Shields G, et al. Characterizing metabolic abnormality and adipose tissue infiltration in skeletal muscle of COPD patients using 31P MR spectroscopy and MRI imaging. Eur Respir J 2012; 40: Suppl. 56, 284s.
19. Giavedoni S, Drost E, Lakhdar R, et al. Reduced mitochondrial density in the vastus lateralis muscle of COPD patients with low fat free mass. Eur Respir J 2012; 40: Suppl. 56, 284s.
20. Vogiatzis I, Terzis G, Stratakos G, et al. Effect of pulmonary rehabilitation on peripheral muscle fiber remodeling in patients with COPD in GOLD stages II to IV. Chest 2011; 140: 744-752.
21. Gouzi F, Préfaut C, Abdellaoui A, et al. Blunted muscle angiogenic response after exercise training in COPD patients. Eur Respir J 2012; 40: Suppl. 56, 284s.
22. Hoier B, Nordsborg N, Andersen S, et al. Pro- and anti-angiogenic factors in human skeletal muscle in response to acute exercise and training. J Physiol 2012; 590: 595-606.
23. Heinzelmann I, Gehlert S, Clever A, et al. Effects of a 3-week inpatient pulmonary rehabilitation (PR) on muscle remodelling in patients with emphysema. Eur Respir J 2012; 40: Suppl. 56, 284s.
24. Vogiatzis I, Simoes DC, Stratakos G, et al. Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD. Eur Respir J 2010; 36: 301-310.
25. Waschki B, Schaper M, Sack AL, et al. Decrease of physical activity in patients with COPD in the course of the disease. Eur Respir J 2012; 40: Suppl. 56, 548s.
26. Ng LW, Mackney J, Jenkins S, et al. Does exercise training change physical activity in people with COPD? A systematic review and meta-analysis. Chron Respir Dis 2012; 9: 17-26.
27. Hospes G, Bossenbroek L, Ten Hacken NH, et al. Enhancement of daily physical activity increases physical fitness of outclinic COPD patients: results of an exercise counseling program. Patient Educ Couns 2009; 75: 274-278.
28. Wewel AR, Gellermann I, Schwertfeger I, et al. Intervention by phone calls raises domiciliary activity and exercise capacity in patients with severe COPD. Respir Med 2008; 102: 20-26.
29. Prosch H, Schaefer-Prokop C, Eisenhuber E, et al. CT protocols in interstitial lung diseases. A survey among members of the European Society of Thoracic Imaging. Eur Respir J 2012; 40: Suppl. 56, 26s.
30. Brashier B, Kajale S, Tambe S, et al. High resolution CT scan (HRCT) thorax differences between biomass-smoke exposure induced COPD (BM COPD) and tobacco-smoking COPD (TS COPD). Eur Respir J 2012; 40: Suppl. 56, 25s.
31. Marshall H, Deppe M, Parra-Robles J, et al. MRI of delayed-ventilation perfusion matching in COPD. Eur Respir J 2012; 40: Suppl. 56, 43s.
32. Zhang W, Hubbard P, Bondesson E, et al. MRI equilibrium signal mapping is a quantitative and reproducible alternative to CT for the estimation of lung density in COPD. Eur Respir J 2012; 40: Suppl. 56, 43s.
33. Garpered S, Edenbrandt L, Valind S, et al. Measurement of airway inflammation in smokers by means of positron emission tomography. Eur Respir J 2012; 40: Suppl. 56, 44s.
34. Parr DG. Quantitative 18FDG PET-CT for the assessment of pulmonary neutrophilic inflammation in COPD. Eur Respir J 2012; 40: Suppl. 56, 100s.
35. Swift A, Rajaram S, Capener D, et al. Non-invasive estimation of pulmonary artery pressure and resistance with CMR imaging: Derivation and prospective validation cohort study. Eur Respir J 2012; 40: Suppl. 56, 44s.
36. Swift A, Rajaram S, Capener D, et al. Prognostic value of ventricular volumes and function in patients with pulmonary hypertension due to chronic obstructive pulmonary disease. Eur Respir J 2012; 40: Suppl. 56, 290s.
37. Sciurba FC, Ernst A, Herth FJ, et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 2010; 363: 1233-1244.
38. Herth FJ, Noppen M, Valipour A, et al. Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. Eur Respir J 2012; 39: 1334-1342.
39. Herth FJ, Eberhardt R, Gompelmann D, et al. Radiological and clinical outcomes of using ChartisTM to plan endobronchial valve treatment. Eur Respir J 2012; 41; 302-308.
40. Gompelmann D, Eberhardt R, Slebos DJ, et al. Pneumothorax as a predictor of beneficial outcome following endoscopic lung volume reduction. Eur Respir J 2012; 40: Suppl. 56, 864s.
41. Deslee G, Blaas S, Gesierich W, et al. Lung volume reduction coil treatment for patients with emphysema: 6-month multicenter feasibility results. Eur Respir J 2012; 40: Suppl. 56, 865s.
42. Slebos DJ, Blaas S, Deslee G, et al. Heterogeneous and homogenous emphysema both respond to lung volume reduction coil treatment. Eur Respir J 2012; 40: Suppl. 56, 865s.
43. Herth FJF, Ernst A, Hopkins P, et al. The influence of emphysema heterogeneity on the magnitude of benefit following endoscopic thermal vapor ablation (InterVapor) in patients with heterogeneous emphysema. Eur Respir J 2012; 40: Suppl. 56, 863s.
44. Harris M, Leyakathali S, Diver S, et al. Is the EBUS TBNA cytology adequate for EGFR analysis? Eur Respir J 2012; 40: Suppl. 56, 812s.
45. Pari M, Masis M, Baixeras N, et al. Diagnostic yield of ROSE (rapid on-site evaluation) and cell block obtained by endobronchial ultrasonography (EBUS) in patients with lung cancer. Eur Respir J 2012; 40: Suppl. 56, 829s.
46. Wong KY, Ng LY, Tse HN, et al. Complications and diagnostic outcome of endobronchial ultrasound (EBUS) guided transbronchial needle aspiration (TBNA) of mediastinal lymph nodes. Eur Respir J 2012; 40: Suppl. 56, 248s.
47. Wuyts WA, Agostini C, Antoniou K, et al. The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J 2012 [In press DOI: 10.1183/09031936. 00073012].
48. Chilosi M, Doglioni C, Murer B, et al. Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010; 27: 7-18.
49. Armanios M, Blackburn EH. The telomere syndromes. Nature Rev Gen 2012; 13: 693-704.
50. Samara K, Lasithiotaki G, Soufa I, et al. Telomerase expression in idiopathic pulmonary fibrosis (IPF) and non small cell lung cancer (NSCLC). Eur Respir J 2012; 40: Suppl. 56, 114s.
51. Ley B, Ryerson JC, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
52. Ley R, Vittinghoff RM, Elicker TF, et al. Extent of fibrosis by high-resolution computed tomography does not improve prediction of mortality in idiopathic pulmonary fibrosis when added to a simple clinical prediction model. Eur Respir J 2012; 40: Suppl. 56, 512s.
53. Casoni GL, Cavazza A, Dubini A, et al. Identification of the pathologic pattern by transbronchial lung cryobiopsies in patients with fibrosing diffuse parenchymal lung disease. Eur Respir J 2012; 40: Suppl. 56, 512s.
54. Costabel U, Albera A, Bradford W, et al. Analysis of lung function and survival in RECAP: an open-label extension study of Pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF). Eur Respir J 2012; 40: Suppl. 56, 511s.
55. Raghu G, Scholand MB, de Andrade J, et al. Phase 2 trial of FG-3019, anti-CTGF monoclonal antibody in idiopathic pulmonary fibrosis (IPF): preliminary safety and efficacy results. Eur Respir J 2012; 40: Suppl. 56, 511s.
56. Taniguchi H, Kondoh Y, Kimura T, et al. Recombinant thrombomodulin improves survival in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J 2012; 40: Suppl. 56, 512s.
57. Cottin V, Cadranel J, Crestani B, et al. Management of idiopathic pulmonary fibrosis in France: a survey of 1456 pulmonologists. Eur Respir J 2012; 40: Suppl. 56, 564s.
58. Keijsers RG, Heuvel DA, Grutters JC. Imaging the inflammatory activity of sarcoidosis. Eur Respir J 2012 [In press DOI: 10.1183/09031936.00088612].
59. Hostettler K, Studler U, Bratu V, et al. Whole-body magnetic resonance imaging in sarcoidosis to assess extrapulmonary organ involvement. Eur Respir J 2012; 40: Suppl. 56, 4s.
60. Baughman R, Culver D, Cordova F, et al. Bosentan for sarcoidosis associated pulmonary arterial hypertension (BoSAPH) was effective in advanced parenchymal lung disease. Eur Respir J 2012; 40: Suppl. 56, 4s.
61. Dulic-Lakovic E, Hubner M, Muller C, et al. Is the bacterium Tropheryma whippley cause of the disease in a subgroup of patients with presumed sarcoidosis? Eur Respir J 2012; 40: Suppl. 56, 288s.
62. Cerveri I, Corsico A, Tripon B, et al. Pulmonary involvement in patients with Marfan syndrome. Eur Respir J 2012; 40: Suppl. 56, 555s.
63. Vaszar L, Piottante A, Mark W, et al. Coexistent granulomatosis with polyangiitis and Crohn disease: a clinicopathologic description of cases. Eur Respir J 2012; 40: Suppl. 56, 554s.
64. Lisspers K, Larsson K, Stallberg B, et al. COPD in primary care in Sweden - An 11 years epidemiological register study. Eur Respir J 2012; 40: Suppl. 56, 797s.
65. Heerema-Poelman A, Wempe J, Stuive I. Adherence to a maintenance exercise programme 1 year after pulmonary rehabilitation: what are the predictors of drop-out? Eur Respir J 2012; 40: Suppl. 56, 797s.
66. Apte K, Barne M, Madas S, et al. More than 50% of patients visit a general practitioner (GP), general physician (Gen P) or pediatrician (P) in India for respiratory symptoms: results of a one-day point-prevalence study in 2,04,912 patients across 22 states and 5 union territories in In. Eur Respir J 2012; 40: Suppl. 56, 797s.
67. Harris M, Church S, Agarwal S. Validity of spirometry performed in the primary care setting. Eur Respir J 2012; 40: Suppl. 56, 120s.
68. Schermer TR, Jacobs JE, Chavannes NH, et al. Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). Thorax 2003; 58: 861-886.
69. Lopez-Giraldo A, Andrea R, Sobradillo P, et al. Lung function abnormalities in patients with heart failure and preserved ejection fraction. Eur Respir J 2012; 40: Suppl. 56, 555s.
70. Boland M, Tsiachristas A, Kruis A, et al. Are disease management programs for COPD cost-effective? Eur Respir J 2012; 40: Suppl. 56, 796s.
71. Sundh J, Montgomery S, Janson C, et al. Can the organization of COPD care in primary health care centres help preventing exacerbations in COPD patients? Eur Respir J 2012; 40: Suppl. 56, 796s.
72. Syk J, Malinovschi A, Johansson G, et al. Lower incidence of asthma exacerbations with FENO-guided anti-inflammatory treatment: a randomized controlled trial. Eur Respir J 2012; 40: Suppl. 56, 797s.
73. Boonsawat W, Thepsuthammarat K. Reducing asthma admission: impact of the easy asthma clinic network. Eur Respir J 2012; 40: Suppl. 56, 797s.
74. Vaske I, Stenzel N, Rief W, et al. End of life fears in COPD: The influence of biomedical variables, mental health status and disease specific anxieties. Eur Respir J 2012; 40: Suppl. 56, 547s.
75. Janssen DJ, Spruit MA, Schols J, et al. Dynamic preferences for site of death among patients with advanced chronic organ failure. Eur Respir J 2012; 40: Suppl. 56, 548s.
76. Kaufman M, Elkwood A, Rose M, et al. The role of nerve transplantation in the management of symptomatic diaphragm paralysis. Eur Respir J 2012; 40: Suppl. 56, 287s.